Get Live Data

Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

  2. Share Prices
  3. ValiRx Share Price
  4. ValiRx Share Regulatory News
  5. General Meeting - Adjournment

Pin to quick picksValiRx Regulatory News (VAL)

ValiRx Information

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.05
Bid: 3.00
Ask: 3.10
Change: -0.05 (-1.61%)
Spread: 0.10 (3.333%)
Open: 3.10
High: 3.15
Low: 3.05
Prev. Close: 3.10
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

General Meeting - Adjournment

25 Mar 2020 09:44

RNS Number : 5351H
ValiRx PLC
25 March 2020
 

ValiRx Plc

("ValiRx" or the "Company")

 

GENERAL MEETING - Adjournment

 

London, UK. 25 March 2020: ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, provides an update on its Notice of General Meeting ("GM"), which was due to be held today at 11:00.

 

Due to the current COVID-19 situation, the meeting has been adjourned until further notice.

 

A further announcement will be made in due course.

 

For more information, please contact:

 

ValiRx plc

Tel: +44 (0) 20 7073 2628

www.valirx.com

Dr Satu Vainikka, Chief Executive

Tel: +44 (0) 20 7073 2628

Tarquin Edwards, Head of Communications.

Tel: +44 (0) 7879 458 364

tarquin.edwards@valirx.com

 

Cairn Financial Advisers LLP - Nominated Adviser

 

Liam Murray / Jo Turner

 

Tel: +44 (0) 20 7213 0880

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCEANDSALAEEEA
12345678910
Date   Source Headline
22nd Apr 20247:00 amRNSDirectorate Changes
21st Mar 20247:00 amRNSEvaluation Agreement with Imperial College London
19th Mar 20247:00 amRNSBoard Re-structuring and update on requisition
4th Mar 20245:47 pmRNSShareholder Requisition Notice
4th Mar 20247:00 amRNSProposed Appointment of Non-Executive Director
29th Feb 20242:00 pmRNSProposed Appointment of Non-Executive Director
13th Feb 20242:20 pmRNSFurther re Shareholder Requisition Notice
9th Feb 20245:06 pmRNSShareholder Requisition Notice
19th Jan 20247:00 amRNSChange of Broker
18th Jan 20247:00 amRNSDirectorate Change
4th Jan 20241:48 pmRNSResult of GM, Issue of Equity
19th Dec 20236:11 pmRNSResult of Retail Offer, Subscription
15th Dec 20237:00 amRNSPosting of Circular, Notice of GM and Ops Review
13th Dec 20234:56 pmRNSRetail Offer
13th Dec 20234:49 pmRNSConditional Fundraise, Notice of General Meeting
5th Dec 20237:00 amRNSAgreement to License VAL401 to Ambrose Healthcare
10th Nov 20237:00 amRNSEvaluation Agreement with StingRay Bio
6th Oct 202310:45 amRNSStatement re Share Price Movement
28th Sep 20237:00 amRNSOperational Review
24th Aug 20237:00 amRNSHalf-year Report
14th Aug 20237:00 amRNSCollaborative Services Agreement
19th Jul 20237:00 amRNSInaphaea BioLabs secures first external contract
28th Jun 20232:15 pmRNSResult of AGM
20th Jun 20237:00 amRNSVirtual AGM Access
19th Jun 20237:00 amRNSInaphaea BioLabs Operational Update
16th Jun 20237:00 amRNSConclusion of Hokkaido Evaluation Agreement
14th Jun 20237:00 amRNSAsset Purchase – Imagen Therapeutics
8th Jun 20237:00 amRNSUpdate on proposed sub-license of VAL201
7th Jun 20237:00 amRNSExpanded agreement with University of Barcelona
5th Jun 20237:00 amRNSFinal Results and Notice of AGM
26th May 20237:00 amRNSNotice of Results and Investor Webinar
26th Apr 20237:00 amRNSCollaborative Services Agreement
31st Mar 20237:00 amRNSQuarterly Operational Update
1st Mar 20237:02 amRNSInvestor Webinar
1st Mar 20237:00 amRNSIncorporation of Inaphaea BioLabs Limited
24th Feb 20234:40 pmRNSSecond Price Monitoring Extn
24th Feb 20234:35 pmRNSPrice Monitoring Extension
2nd Feb 202312:45 pmRNSResult of GM, Issue of Equity
31st Jan 20237:02 amRNSOperational Update
31st Jan 20237:00 amRNSHolding(s) in Company
17th Jan 20234:36 pmRNSBroker Offer Results
17th Jan 20239:22 amRNSPosting of Circular and Notice of General Meeting
13th Jan 20237:01 amRNSLaunch of Broker Offer
13th Jan 20237:00 amRNSIssue of Equity & Proposed Broker Offer
14th Dec 20225:01 pmRNSHolding(s) in Company
7th Dec 20221:06 pmRNSHolding(s) in Company
6th Dec 20224:40 pmRNSSecond Price Monitoring Extn
6th Dec 20224:35 pmRNSPrice Monitoring Extension
6th Dec 202212:00 pmRNSShareholder Communications and Investor Webinar
6th Dec 20227:00 amRNSQuarterly Operational and Strategy Update
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.